Market Cap | 281.35M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -7.65M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 3.00% |
Sales | 705.24k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -16.00% |
Dividend | N/A | Price/Book | 42.39 | EPS next 5Y | - | 52W High Chg | -52.00% |
Recommedations | - | Quick Ratio | 3.65 | Shares Outstanding | 99.07M | 52W Low Chg | 109.00% |
Insider Own | 3.85% | ROA | -27.21% | Shares Float | 94.73M | Beta | 0.81 |
Inst Own | - | ROE | -44.97% | Shares Shorted/Prior | -/- | Price | 2.84 |
Gross Margin | 36.33% | Profit Margin | - | Avg. Volume | 291,027 | Target Price | - |
Oper. Margin | -1,120.95% | Earnings Date | Nov 29 | Volume | 38,888 | Change | 0.00% |
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite Project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating; and surgical masks, HVAC filters, and personal protective equipment. It is also developing synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is based in Thunder Bay, Canada.